Share Prices & Company Research

Stockbroking

GlaxoSmithKline

Current Price 1729.00p Bid 1728.60p Ask 1729.20p Change -0.88%
Last Updated: 13/12/2019 13:08. Prices delayed by at least 15 minutes.
Call 0113 243 6941 or search for your local office

Company Overview

GlaxoSmithKline (GSK) is a world leading research-based pharmaceutical company with a powerful combination of skills and resources that provides a platform for delivering strong growth in today's rapidly changing healthcare environment. Headquartered in the UK and with operations based in the US, the new company is one of the industry leaders, with an estimated seven per cent of the world's pharmaceutical market. GSK also has leadership in four major therapeutic areas - anti-infectives, central nervous system (CNS), respiratory and gastro-intestinal/metabolic. In addition, it is a leader in the important area of vaccines and has a growing portfolio of oncology products. The company also has a Consumer Healthcare portfolio comprising over-the-counter (OTC) medicines, oral care products and nutritional healthcare drinks, all of which are among the market leaders. GSK has over 100,000 employees worldwide. Of these, over 40,000 are in sales and marketing, the largest sales force in the industry. Around 35,000 employees work at 82 manufacturing sites in 37 countries and over 15,000 are in R&D. GSK R&D is based at 24 sites in 11 countries. The company has a leading position in genomics/genetics and new drug discovery technologies. The GSK R&D budget is about £2.8bn/$5bn.

Financial Highlights Year Ended 31/12/2018

Turnover
£30,821.00m
Operating Profit
£5,483.00m
Dividend Yield
4.56
Dividend Per Share
80.00
Dividend Cover
0.92
P/E Ratio
23.79

Key Personnel

Emma Natasha Walmsley
Chief Executive Officer
Iain James Mackay
Chief Financial Officer
Dr Hal Barron
Chief Scientific Officer
Jonathan Richard Symonds
Non-Executive Chairman
Lynn Laverty Elsenhans
Non-Executive Director
Dr Laurie Hollis Glimcher
Non-Executive Director
Dr Jesse Goodman
Non-Executive Director
Urs Rohner
Non-Executive Director
Judith Carol Lewent
Non-Executive Director
Dr Vivienne Cox
Non-Executive Director
Manvinder Singh Banga
Non-Executive Director

Stock Details

EPIC
GSK
ISIN
GB0009252882
Shares in Issue
4,989,321,504
Market cap
£87,462.81m

Analyst Views (11)

Strong Buy
 
36.36%
Buy
 
0.00%
Hold
 
63.64%
Sell
 
0.00%
Strong Sell
 
0.00%
The above information represents a selection of the views published in the last 120 days by analysts. It is subject to change without notice and doesn't reflect view held by Redmayne Bentley and is not advice.

Price Summary

Mid Price
1728.90p
Bid Price
1728.60p
Ask Price
1729.20p
Volume
4759242
Change Today
-15.30p
% Change Today
-0.88%
Open
1701.00p
Previous Close
1744.20p
Intraday High
1735.40p
Intraday Low
1656.80p
52 Week High
1796.40p
52 Week Low
1421.80p
52 week high and low figures quoted above are calculated from intraday price data.

Intra-Day Chart

GlaxoSmithKline Intra-day Chart

GlaxoSmithKline News

News in this section is provided by AJ Bell

Broker Forecast - Deutsche Bank issues a broker note on GlaxoSmithKline PLC 12 Dec 2019 | 08:40 Broker Forecast - UBS issues a broker note on GlaxoSmithKline PLC 21 Nov 2019 | 09:50 Broker Forecast - Liberum Capital issues a broker note on GlaxoSmithKline PLC 04 Nov 2019 | 10:30 Broker Forecast - Barclays Capital issues a broker note on GlaxoSmithKline PLC 01 Nov 2019 | 10:10 Broker Forecast - DZ Bank issues a broker note on GlaxoSmithKline PLC 31 Oct 2019 | 09:50 Broker Forecast - Credit Suisse issues a broker note on GlaxoSmithKline PLC 31 Oct 2019 | 09:40 UK stocks close higher on exporter strength and dollar earners as investors eye Fed rate cut 30 Oct 2019 | 17:04 Director Deals - GlaxoSmithKline PLC (GSK) 15 Oct 2019 | 17:15 Director Deals - GlaxoSmithKline PLC (GSK) 15 Oct 2019 | 17:15 UK stocks turn slightly lower at midday 30 Sep 2019 | 12:03 UK stocks edge higher as Brexit, trade tensions simmer 30 Sep 2019 | 09:11 Broker Forecast - Deutsche Bank issues a broker note on GlaxoSmithKline PLC 02 Sep 2019 | 08:50 Trade fears see FTSE 100 surrender gains 23 Aug 2019 | 16:42 FTSE firms ahead of Fed chair speech 23 Aug 2019 | 12:12 UK stocks open 0.6% higher as Entertainment One gets takeover bid 23 Aug 2019 | 08:54 GlaxoSmithKline blood cancer treatment meets primary objective in clinical trial 23 Aug 2019 | 07:16 UK market accelerates decline as US open fails to lift Fed rate rise doubts 22 Aug 2019 | 17:05 Fed rate worries continue to drag on UK markets, buyout talk rallies NMC Health 22 Aug 2019 | 12:14 UK stocks fall as market digests Fed minutes 22 Aug 2019 | 09:37 GlaxoSmithKline's JV ViiV Healthcare says trial of injectable HIV treatment met objectives 22 Aug 2019 | 07:41 GlaxoSmithKline submits renal anaemia drug application in Japan 21 Aug 2019 | 08:58 Broker Forecast - JP Morgan Cazenove issues a broker note on GlaxoSmithKline PLC 13 Aug 2019 | 09:00 GlaxoSmithKline, Pfizer complete formation of consumer healthcare joint venture 01 Aug 2019 | 09:01 GlaxoSmithKline submits marketing application to European Medices Agency for HIV treatment 29 Jul 2019 | 09:34 Broker Forecast - Deutsche Bank issues a broker note on GlaxoSmithKline PLC 26 Jul 2019 | 12:40 GlaxoSmithKline upgrades guidance amid bumper shingles vaccine sales 24 Jul 2019 | 13:10 Broker Forecast - UBS issues a broker note on GlaxoSmithKline PLC 23 Jul 2019 | 10:10 FTSE boosted by sterling weakness 15 Jul 2019 | 16:22 FTSE regains its poise by lunchtime 15 Jul 2019 | 12:07 UK stocks open slightly higher after mixed Chinese economic data 15 Jul 2019 | 08:57

Assets (£m)

Data has been provided by AJ Bell

Reporting Date
31 Dec 2018
31 Dec 2017
Tangible Assets
11,058.0
10,860.0
Intangible Assets & Goodwill
22,991.0
23,296.0
Investments & Other Non-Current Assets
7,090.0
6,318.0
Total Non-Current Assets
41,139.0
40,474.0
Inventory
5,476.0
5,557.0
Trade & Receivables
6,423.0
6,000.0
Cash & Receivables
3,874.0
3,833.0
Other Current Assets & Assets Held for Resale
1,154.0
517.0
Total Assets
58,066.0
56,381.0

Liabilities (£m)

Data has been provided by AJ Bell

Reporting Date
31 Dec 2018
31 Dec 2017
Short Term Liabilities
22,491.0
26,569.0
Long Term Liabilities
31,903.0
26,323.0
Other Liabilities / Pension etc
0.0
0.0
Total Liabilities
54,394.0
52,892.0

Net Assets (£m)

Data has been provided by AJ Bell

Reporting Date
31 Dec 2018
31 Dec 2017
Net Assets
3,672.0
3,489.0

Equity (£m)

Data has been provided by AJ Bell

Reporting Date
31 Dec 2018
31 Dec 2017
Share Capital
1,345.0
1,343.0
Minority Interests
-688.0
3,557.0
Retained Earnings
-2,137.0
-6,477.0
Share Premium Account
3,091.0
3,019.0
Other Equity
2,061.0
2,047.0
Total Equity
3,672.0
3,489.0

Cashflow (£m)

Data has been provided by AJ Bell

Reporting Date
31 Dec 2018
31 Dec 2017
Cashflow from Operating Activities
8,421.0
6,918.0
Cashflow Before Financing
6,868.0
5,475.0
Increase / Decrease in Cash
479.0
-905.0

Income (£m)

Data has been provided by AJ Bell

Reporting Date
31 Dec 2018
31 Dec 2017
Turnover
30,821.0
30,186.0
Cost of Sales
10,241.0
10,342.0
Gross Profit
20,580.0
19,844.0
Operating Profit
5,483.0
4,087.0
Pre-Tax Profit
4,800.0
3,525.0
Profit / Loss for the Year
4,046.0
2,169.0

Dividend History

Data has been provided by AJ Bell

Period
Ex-Dividend Date
Payment Date
H1 Dividend
08 Aug 2019
10 Oct 2019
Q1 Dividend
16 May 2019
11 Jul 2019
H2 Dividend
21 Feb 2019
11 Apr 2019
Q3 Dividend
15 Nov 2018
10 Jan 2019
H1 Dividend
09 Aug 2018
11 Oct 2018
Q1 Dividend
10 May 2018
12 Jul 2018
H2 Dividend
22 Feb 2018
12 Apr 2018
Q3 Dividend
09 Nov 2017
11 Jan 2018
H1 Dividend
10 Aug 2017
12 Oct 2017
Q1 Dividend
11 May 2017
13 Jul 2017
H2 Dividend
23 Feb 2017
13 Apr 2017
Q3 Dividend
03 Nov 2016
12 Jan 2017
H1 Dividend
11 Aug 2016
13 Oct 2016
Q1 Dividend
12 May 2016
14 Jul 2016
Special Dividend
18 Feb 2016
14 Apr 2016
H2 Dividend
18 Feb 2016
14 Apr 2016
Q3 Dividend
12 Nov 2015
14 Jan 2016
H1 Dividend
13 Aug 2015
01 Oct 2015
Q1 Dividend
14 May 2015
09 Jul 2015
H2 Dividend
19 Feb 2015
09 Apr 2015
Q3 Dividend
06 Nov 2014
08 Jan 2015
The value of your investments and the income from them may go down as well as up, and you could get back less than you invested.
We use cookies on this site to improve your experience and help us provide you with a better website. An explanation of the cookies we use and their purpose can be found within our Cookie Policy. Your continued use of this site means you consent to the use of cookies.